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Aims Although electrical cardioversion (CV) is effective in restoring sinus rhythm in patients with atrial fibrillation (AF), AF
frequently recurs in spite of antiarrhythmic medications. We investigated the predictors of failed CV and AF recur-
rence after successful CV.
Methods
and results
In 81 patients (M:F ¼ 63:18, 59.1+ 10.5 years old) with AF who underwent CV, clinical, image, and CV findings
(energy requirement, immediate recurrence of AF , 15 min), and pre-CV serological markers were evaluated.
Results: (i) During 13.1+ 10.6 months of follow-up, 8.6% (7/81) showed failed CV, 59.26% (48/81) showed AF recur-
rence, and 32.1% (26/81) remained in sinus rhythm (no recurrence). (ii) Failed CV showed higher plasma levels of
transforming growth factor (TGF)-b (P ¼ 0.0260) than those with successful CV. (iii) Patients with AF recurrence
were older (60.4+9.0 years old vs. 55.3+ 12.5years old, P ¼ 0.0220), had a higher incidence of spontaneous
echo contrast (SEC; 68.1 vs. 40.0%, P ¼ 0.0106), a lower prescription rate of angiotensin-converting enzyme inhibitor
(ACE-I)/angiotensin receptor blocker (ARB; 27.0 vs. 50.0%, P ¼ 0.0248) or spironolactone (0.0 vs. 19.2%,
P ¼ 0.0007), and lower plasma levels of stromal cell-derived factor (SDF)-1a (P ¼ 0.0105).
Conclusion Post-CV recurrence commonly occurs in patients with age .60 years, SEC, under-utilization of ACE-I/ARB or spir-
onolactone, and low plasma levels of SDF-1a. High plasma level of TGF-b predicts failed CV.
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Introduction
Atrial fibrillation (AF) is themost common cardiac arrhythmia in clini-
cal practice, leading to significantmorbidity and disability and resulting
in limited quality of life.1 It has been reported that appropriate rhythm
control may have a mortality benefit in patients with AF.2,3 Although
electrical cardioversion (CV) is known to be effective in restoring
sinus rhythm in patients with persistent AF (PeAF), AF frequently
recurred in spite of concomitant medication with antiarrhythmic
drugs (AAD).4,5 Approximately 50% of patients who successfully car-
diovert initially experience AF recurrencewithin the first month after
CV.6,7 This is due to significant electrical remodelling,8 structural
changes of the atrial myocardium in patients with AF,9,10 and the
limitations of AAD.2,4,5 Although there have been several
reports,11,12 the predictors of successful CV or long-term mainten-
ance of sinus rhythm in patients with PeAF are not yet clear. The
development of appropriate clinical and serological predictors for
recurrence after CV may reduce the number of unnecessary pro-
cedures, the risk of complications, and medical costs and may
improve the clinical outcome of highly selected patients. Discovering
predictors for post-CV recurrence also would contribute to the
understanding of AF pathophysiology. Therefore, we investigated
whether certain pre-CV factors, such as clinical parameters, imaging
analyses, CV findings, and serological parameters related to matrix
remodelling, fibrosis, atrial stretching, and chemotaxis, can predict
failure or recurrence of AF after electrical CV.
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This study was approved by the Institutional Review Board of Anam
Hospital of Korea University. All patients provided written informed
consent. Eighty-one patients with PeAF (male: female ¼ 63:18, mean
age 59.1+10.5 years old) who underwent external electrical CV
were included in the study. Patients with history of any previous
CV, significant mitral valvular heart disease, huge left atrium (LA).
55 mm, a recent infection, surgery or acute coronary syndrome in
the 2 months prior to the collection of blood samples were excluded.
All patient maintained optimal anticoagulation, had been taking AAD
for at least 1 month, and maintained them after CV. Trans-esophageal
echocardiography was done to exclude intra-cardiac thrombus and to
determine the existence of spontaneous echo contrast (SEC) on the
same day of CV in every patient. The blood samples for the serological
assays were drawn before sedation for external CV.
Electrical cardioversion protocol
After obtaining written informed consent, electrical CV was per-
formed under sedation with intravenous midazolam (0.05 mg/kg) and
thio-pental sodium (60 mg/kg). A biphasic R-wave synchronized
shock (Lifepak12, Physiocontrol Ltd, Redmond, WA, USA) was
applied to the patients via self-adhesive skin electrodes (TZ Medical
Inc., Portland, OR, USA) in an anterior–posterior position. We deliv-
ered an initial CV with 70 J. If the initial shock failed to terminate AF,
the biphasic shock energy was gradually increased to 100, 150, and
then 200 J serially (5 min intervals). If CV terminated AF successfully,
the patient’s cardiac rhythm was monitored for 15 min to detect an
atrial premature complex (APC) or recurrence of AF. If AF returned
within 15 min of termination by CV, we defined it as immediate recur-
rence of AF (IRAF). In patients with IRAF or frequent APCs, amiodar-
one 150 mg was administered intravenously and the same energy
shock was repeated. Patients in whom AF remained even after 200 J
CV or who exhibited repeated IRAF in spite of amiodarone were
defined as failed CV.
Biochemical analyses
We took 5 mL of peripheral blood immediately before CV to measure
the plasma levels of several protein markers or chemokines by enzyme
linked immuno-sorbent assay (ELISA): pro-atrial natriuretic peptide
(ANP; Biomedica, Antony, France), matrix metalloproteinase
(MMP)-9, transforming growth factor (TGF)-b, and stromal cell-
derived factor (SDF)-1a (R&D Systems, Minneapolis, MN, USA).
High sensitivity (hs) C-reactive protein was measured on a Hitachi
912 assay system (Roche Diagnostics, Indianapolis, IN, USA) using
the Kamiya K-assay (Kamiya Biomedical Corp., Seattle, WA, USA),
which quantitatively determines C-reactive protein by latex
particle-enhanced immunoturbidimetric assay. We use the average
values of chemokine assays with duplicated plasma samples with differ-
ence , 10% of lower value to secure the reproducibility.
Follow-up of patients
After CV, all patients were prospectively followed-up at outpatient
clinic at 1, 2, 4, 8 weeks, and then every 3 months thereafter. Elecro-
cardiography (ECG) was performed at every visit or anytime the
patient reported palpitations. A Holter ECG (24 or 48 h) and/or
event recorder was evaluated at 2 months in patients who did not
recur. We classified the patients into three different groups according
to clinical outcome as follows: (i) failed CV, (ii) AF recurrence after
successful CV, and (iii) no recurrence.
Statistical analysis
We evaluated the clinical factors [e.g. age, sex, LA size, ejection frac-
tion (EF), SEC, and medication, such as angiotensin-converting
enzyme inhibitor (ACE-I), angiotensin receptor blocker (ARB), spiro-
nolactone, statin, and b-adrenoceptor blocker], CV findings (IRAF,
post-CV APCs, final CV shock energy, intravenous amiodarone after
failed AF termination), and serological factors (MMP-9, SDF-1a,
TGF-b, pro-ANP, and hs-C-reactive protein) in terms of success or
failure and the timing of recurrence. Comparisons between groups
were analysed by the Mann–Whitney test or a t-test. In order to ident-
ify the predictors of failed CV or AF recurrence, univariate and multi-
variate logistic regression analyses and Cox regression analysis were
performed. Atrial fibrillation free rates were compared in terms of
clinical and serological parameters by utilizing Kaplan–Meier curves.
All values were expressed as mean+ SD. All statistical analyses
were performed using SPSS version 12.0 and a P-value of less than
0.05 was considered statistically significant.
Results
Patient characteristics and clinical
outcomes
We performed external electrical CV in 81 patients (59.1+10.5
years old, 63 males) with PeAF. The mean LA size was 45.5+
6.0 mm, the mean EF of the LV was 48.7+ 15.1%, and 57.7% of
patients had SEC in LA. Angiotensin-converting enzyme inhibitor
or ARB was prescribed in 30.9% of patients. The prescription
rates of spironolactone, b-blocker, and statin were 7.4, 28.4, and
9.9%, respectively. All patients had been taking AAD for at least
1 month before and after CV (amiodarone 60.5%, other class IC
AAD 39.5%). The mean number of electrical shock performed
was 1.9+ 1.4, the final successful CV energy was 96.7+ 32.3 J,
and the cumulative CV energy was 170.4+ 178.5 J. Then 53.8%
showed frequent APC after CV, and 9.9% showed IRAF; and
22.2% received intravenous amiodarone due to repeated IRAF or
frequent APCs. Among the 81 patients, 8.6% (7/81) showed
failed CV and 91.4% (74/81) underwent successful CV. We
followed-up those 74 patients after successful CV for 13.2+
11.0 months; and 64.9% (48/74) recurred AF and 35.1% (26/74)
remained in sinus rhythm during the follow-up period. Among
the patients with AF recurrence, a median time to recurrence
was median time 21.0+106.6 days after CV, and 45.8% (22/48)
recurred within 2 weeks after CV.
Predictors for failed electrical
cardioversion
Between the patients with failed CV and successful CV, there were
no significant differences in age (63.7+ 8.5 vs. 58.62+ 10.6 years
old, P ¼ 0.1104), sex (male 85.7 vs. 77.0%, P ¼ 0.3013), LA size
(42.5+ 6.9 vs. 45.8+5.9 mm, P ¼ 0.1037), EF (44.7+ 24.4 vs.
49.1+ 14.1%, P ¼ 0.2326), the existence of SEC (50.0 vs. 58.3%,
P ¼ 0.3480), or medications. However, the prescription rate of
amiodarone was lower in patients with failed CV compared with
those with successful CV (28.6 vs. 64.9%, P ¼ 0.0301). Immediate
recurrence of AF was more common in the failed CV compared
with the successful CV group (71.4 vs. 4.1%, P, 0.0001). The
pre-CV plasma level of TGF-b, which reflects the degree of



















fibrosis, was significantly higher in patients with failed CV (22.7+
22.9 ng/mL) than in those with successful CV (13.5+9.8 ng/mL,
P ¼ 0.0260). In the univariate logistic regression analysis, the exist-
ence of IRAF (OR 0.017, 95% CI 0.002–0.126, P, 0.001), and a
high final CV energy (OR 0.979, 95% CI 0.959–1.000, P ¼ 0.046)
were closely related to failed CV.
Predictors for recurrence after successful
electrical cardioversion
The recurrence rate of AF after successful CV was 64.9% (48/74)
during the 13.2+ 11.0 months follow-up. Table 1 summarizes
comparisons of the clinical and serological parameters in the
patients. The patients who showed AF recurrence were older
than those without recurrence (60.4+ 9.0 vs. 55.3+12.5 years
old, P ¼ 0.0220). Although there was no significant difference in
either body mass index, LA size or EF, SEC more commonly
occurred in patients with AF recurrence (68.1%) than in those
without recurrence (40.0%, P ¼ 0.0106). The prescription rates
of ACE-I/ARB (27.1 vs. 50.0%, P ¼ 0.0248) and spironolactone
(0.0 vs. 19.2%, P ¼ 0.0007) were significantly lower in AF recur-
rence group. However, b-blockers or statin did not affect clinical
outcomes. The recurrence rates were 66.7% (32/48) in patients
with amiodarone and 61.5% (16/26) in those with class IC AAD
(P ¼ 0.3780). Pre-CV plasma levels of SDF-1a (3.2+ 1.2 vs.
3.9+ 0.8 ng/mL, P ¼ 0.0105) and pro-ANP (4.9+4.3 vs. 6.7+
4.1 nmol/L, P ¼ 0.0477) were lower in patients with AF recurrence
than in those without recurrence. In the univariate logistic
regression analyses, it is shown that old age (OR 1.053, 95% CI
1.004–1.053, P ¼ 0.035), the existence of SEC (OR 2.833, 95%
CI 1.060–7.573, P ¼ 0.038), under-utilization of spironolactone
(OR 0.079, 95% CI 0.009–0.719, P ¼ 0.024), and lower SDF-1a
(OR 0.603, 95% CI 0.379–0.960, P ¼ 0.033) may predict AF recur-
rence. In the multivariate logistic regression analysis, the existence
of SEC (OR 3.960, 95% CI 1.263–12.423, P ¼ 0.018) and low
SDF-1a (OR 0.537, 95% CI 0.302–0.954, P ¼ 0.034) were inde-
pendent risk factors for AF recurrence. In the multivariate Cox
regression analysis, age (HR 1.603, 95% CI 1.008–1.075, P ¼
0.015) was an independent risk factor for AF recurrence. In
Kaplan–Meier analyses, the AF recurrence rate was higher in
patients who were older than 60 (P ¼ 0.0295), did not take spiro-
nolactone (P ¼ 0.0263), and had plasma SDF-1a, 3.0 ng/mL (P ¼
0.0114, Figure 1). There was no specific serological predictor that
can predict early vs. late recurrence of AF after CV.
Spontaneous echo contrast or left atrium
size-dependent parameters
In patients with SEC, the LA size was larger (47.1+6.1 vs. 43.3+
5.4 mm, P ¼ 0.0031), the incidence of heart failure was higher
(28.9 vs. 6.1%, P ¼ 0.0055), and pre-CV plasma levels of
pro-ANP were higher (6.42+ 4.29 vs. 4.46+4.00 nmol/L, P ¼
0.0221) when compared with those without SEC (Table 2).
The rate of AF recurrence was also higher (77.3 vs. 54.5%, P ¼
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Table 1 Comparison of patients with atrial fibrillation recurrence and without recurrence after successful cardioversion
Recurrence (n5 48) No recurrence (n5 26) P-value
Male (%) 81.25 69.23 0.1233
Age (years) 60.44+8.99 55.27+12.52 0.0220
Hypertension (%) 25.0 34.6 0.1940
Heart failure (%) 18.8 15.4 0.3605
Body mass index (kg/m2) 24.2+2.9 25.5+3.5 0.0731
LA size (mm) 46.15+5.08 45.05+6.63 0.2286
EF (%) 48.93+14.51 49.50+13.67 0.4346
SEC (%) 68.1 40.0 0.0106
ACE-I/ARB (%) 27.01 50.0 0.0248
b-Blocker (%) 18.75 34.62 0.1125
Spironolactone (%) 0.00 19.23 0.0007
Statin (%) 8.33 15.38 0.1789
Amiodarone (%) 66.7 61.5 0.3321
J final (J) 91.95+30.10 97.78+36.06 0.2617
IRAF (%) 6.25 0.00 0.0991
IV AAD (%) 12.50 19.23 0.2220
APC (%) 59.57 50.0 0.2184
Bradycardia (%) 6.67 0.00 0.0961
MMP-9 (ng/mL) 124.28+75.80 121.58+40.60 0.4348
SDF-1a (ng/mL) 3.242+1.24 3.88+0.80 0.0105
TGF-b (ng/mL) 13.38+8.15 13.61+11.93 0.4652
Pro-ANP (nmol/L) 4.92+4.36 6.68+4.09 0.0477
Hs-C-reactive protein (ng/mL) 4.29+11.20 4.01+12.68 0.4616
Time to recurrence (days) 51.17+106.58 0.00+0.00 0.0086



















0.0177) and the time to recurrence was later (34.6+66.3 vs.
11.7+21.4 days, P ¼ 0.0365) in patients with SEC. However,
the existent of SEC did not affect the rate of failed CV or other
CV findings (Table 2). In patients with IRAF, the LA size was
smaller than in those without IRAF (40.7+4.6 vs. 46.0+
5.9 mm, P ¼ 0.0123).
We also compared patients with LA 45 mm to those with LA
,45 mm (Table 3). In patients with LA 45 mm, the incidence of
Figure 1 Kaplan–Meier curves suggest higher recurrence rate of AF after successful CV in patients with age .60 years old (A), and SDF-1a
3.0 ng/mL (B).
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Table 2 Comparison of patients with spontaneous echo contrast and without spontaneous echo contrast
SEC1 (n5 45) SEC2 (n5 36) P-value
Male (%) 73.00 85.00 0.1100
Age (years) 59.22+9.67 59.70+10.12 0.4171
Hypertension (%) 35.6 21.2 0.0871
Heart failure (%) 28.9 6.1 0.0055
LA size (mm) 47.06+6.05 43.26+5.35 0.0031
EF (%) 49.17+11.87 51.08+14.92 0.2664
ACE-I/ARB (%) 37.78 33.33 0.3453
b-Blocker (%) 24.44 30.30 0.2851
Spironolactone (%) 6.67 9.09 0.3480
Statin (%) 11.11 12.12 0.4460
J success (J) 81.63+25.81 85.00+39.02 0.3270
J final (J) 94.72+24.32 101.11+41.63 0.2238
IRAF (%) 6.67 12.12 0.2058
IV AAD (%) 22.22 21.21 0.4582
APC (%) 52.27 54.55 0.4229
Brady (%) 2.33 6.45 0.1908
MMP-9 (ng/mL) 124.91+59.46 112.60+66.18 0.2145
SDF-1a (ng/mL) 3.56+1.17 3.38+1.02 0.2441
TGF-b (ng/mL) 15.14+10.14 12.00+9.71 0.1031
Pro-ANP (nmol/L) 6.42+4.29 4.46+4.00 0.0221
hs-C-reactive protein (ng/mL) 3.02+9.00 5.45+14.05 0.1892
Failure of CV (%) 6.67 9.09 0.3896
Recurrence (%) 77.27 54.54 0.0177
Time to recurrence (days) 34.61+66.31 11.7+21.43 0.0365



















SEC (69.8 vs. 45.5%, P ¼ 0.0164) was higher, but that of IRAF (2.3
vs. 18.2%, P ¼ 0.0080) was lower. However, the rates of failed CV
and AF recurrence were not affected by LA size. Although the ser-
ological parameters were not different between the two groups,
MMP-9 (139.6+49.97 vs. 107.78+ 65.15 ng/mL, P ¼ 0.0285)
and SDF-1a (3.76+1.26 vs. 3.24+0.99 ng/mL, P ¼ 0.0261)
were significantly higher in patients with LA 48 mm than in
those with LA ,48 mm.
Discussion
In the present study, we prospectively explored the predictors for
failed CV and AF recurrence after electrical CV systemically. We
found that AF recurrence commonly occurred in patients with
age .60 years, SEC, under-utilization of ACE-I/ARB or spironolac-
tone, and low SDF-1a. High plasma level of TGF-b predicts failed
CV. Pre-determination of predictors for failed CV or AF recur-
rence might be useful for clinical decisions on rhythm control strat-
egies and the understanding of pathophysiology in patients with AF.
The roles of upstream therapy after
electrical cardioversion of atrial
fibrillation
Although 50% of patients who are successfully cardioverted
initially experience AF recurrence within the first month after
CV,6,7 AAD and upstream medical therapy are effective in prevent-
ing this. Nakashima et al.13 first suggested the potential role of
angiotensin II inhibitors for preventing atrial electrical and struc-
tural remodelling, and Madrid et al.14 proved its effect in a prospec-
tive randomized clinical study in patients with AF after electrical
CV. Angiotensin-converting enzyme inhibitor15,16 and statin17
also play roles in the inhibition of AF recurrence after CV.
However, two recent randomized trials failed to reproduce the
benefits of ARB.18,19 Although these upstream therapies may
reduce the recurrence rate of AF after electrical CV by preventing
atrial structural remodelling, more clinical data support will be
required.
Immediate recurrence of atrial
fibrillation and left atrium size in the
recurrence of atrial fibrillation after
cardioversion
The pathophysiology of AF is heterogeneous, and, like heart failure,
includes various kinds of heart disease.20 Like the diversity of AF
pathophysiology, the factors related to failed CV or AF recurrence
might be widespread. In our data, IRAF was more common in failed
CV group and in patients with smaller LA (,45 mm) than in those
with LA 45 mm. This finding suggests that an appreciable pro-
portion of AF recurrence after CV in patients with PeAF was
trigger-type AF without significant substrate remodelling or LA
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Table 3 Comparison of patients with left atrium size 45 and <45 mm
LA  45 mm (n5 46) LA < 45 mm (n5 35) P-value
LA size (mm) 49.60+3.54 40.06+3.87 ,0.0001
Male (%) 72.7 87.9 0.0540
Age (years) 58.86+9.68 59.55+10.05 0.3821
Hypertension (%) 32.6 21.2 0.1354
Heart failure (%) 18.2 21.2 0.3719
EF (%) 51.27+8.899 49.81+14.99 0.2969
SEC (%) 69.77 45.45 0.0164
ACE-I/ARB (%) 38.64 30.3 0.2274
b-Blocker (%) 29.55 21.21 0.2079
Spironolactone (%) 11.36 3.03 0.0908
Statin (%) 13.64 6.06 0.1435
J success (J) 83.81+30.92 79.06+26.07 0.2433
J final (J) 92.97+29.33 98.85+31.54 0.2255
IRAF (%) 2.27 18.18 0.0080
IV AAD (%) 15.91 27.27 0.1146
APC (%) 53.49 54.55 0.4641
Bradycardia (%) 7.14 0.00 0.0661
MMP-9 (ng/mL) 124.72+51.56 110.74+71.48 0.1867
SDF-1a (ng/mL) 3.41+1.23 3.40+0.92 0.4809
TGF-b (ng/mL) 14.67+11.05 12.88+9.22 0.2429
Pro-ANP (nmol/L) 5.54+4.18 5.11+4.13 0.3254
hs-C-reactive protein (ng/mL) 3.47+10.71 4.54+12.44 0.3507
Failure of CV (%) 4.55 12.12 0.1125
Recurrence (%) 70.45 62.50 0.2364
Time to recurrence (days) 41.29+104.08 23.83+67.01 0.2150



















enlargement. In those patients with IRAF without significant enlar-
gement of the LA, radiofrequency catheter ablation (RFCA) might
be a better strategy for rhythm control than repeated electrical
CV. An enlarged LA may reflect the degree of structural remodel-
ling and LA pressure and is one of predictors for recurrence after
RFCA of AF.21,22 However, LA diameter was not related to the
failed CV or AF recurrence in this study or other previous
studies.23,24 With this in mind, one may ask why the meaning of
LA diameter is different after electrical CV and RFCA. First,
AAD were maintained after CV, but stopped within third month
after RFCA in most institutes.21 Second, CV does not change
atrial critical mass, but RFCA reduces it which contains multiple
reentries.20 Third, the risk of recurrence after AF ablation is high
in patients with an enlarged LA, because of the potential conduc-
tion gap on the long distance of linear ablation or non-pulmonary
vein foci.25 Forth, patient selection bias also contributes. In con-
trast, the mean LA diameter was 45.5 mm in this study, LA dimen-
sions .65 mm have been reported to be associated with AF
recurrence after CV.24 We previously reported that poor mechan-
ical reserve of the LA appendage predicts AF recurrence,11 and
prolonged atrial stunning after electrical CV is also related to
poor clinical outcomes.26 Therefore, atrial mechanical function
may be more important in clinical outcomes after CV than atrial
morphological changes.
Spontaneous echo contrast and
serological factors after cardioversion
In this study, the existence of SEC and low SDF-1a were indepen-
dent risk factors for AF recurrence. In patients with SEC, the LA
diameter was long and pre-CV plasma levels of pro-ANP were
elevated, but neither LA diameter nor pro-ANP level predicted
AF recurrence. Rather, plasma levels of pro-ANP were slightly
low in patients with recurrence in this study and others.27 This
finding suggests that AF recurrence is affected by LA function,11
and LA diameter or the atrial capability to produce pro-ANP
might be related with the chronicity of AF.
The chemokine SDF-1a has been shown to play a key role in
haematopoietic or endothelial progenitor cell trafficking in the
myocardial ischaemia model.28–30 However, the role of SDF-1a
has been poorly explored in the pathophysiology of AF. Goette
et al.31 report that SDF-1a levels are higher in PeAF than paroxys-
mal AF or controls, and SDF-1a plays some role in the restitution
of haematopoietic progenitor cells after failed CV. The reason for
the high recurrence of AF in patients with low plasma levels of
SDF-1a remains to be studied. Although it has been reported
that high levels of hs-C-reactive protein are associated with an
increased risk of recurrence of AF,12,32 our data and Conway
et al.33 failed to prove its clinical predictive value. The plasma
level of hs-C-reactive protein may be associated with the perma-
nence of AF related to systemic inflammation or prothrombotic
status.34
Study limitations
The patients included in this study were a highly selected group
referred for rhythm control, and the number of patients was
also limited. The exclusion of patients with large atria bigger
than 55 mm may influence the outcomes related to LA size. We
used multivariate logistic regression analysis, because the
purpose of our study was to analyse the relationship between
the recurrence and multiple variables rather than time-dependent
recurrence predictors. Although we found that AF recurrence was
more common in patients who were not taking spironolacton, this
study was not designed to assess the efficacies of ACE-I/ARB or
spironolacton, and the lower recurrence rate may barely reflect
better treated heart failure or hypertension in selected patients.
The peripheral blood samples may only partially reflect the
remote process in the atria. Although we used AAD in all patients
before and after CV, the proportion of amiodarone was 60.5% (49/
81). We performed CV from 70 J biphasic shock which is lower
than ACC/AHA/ESC 2006 guideline,35 but the initial success rate
with 70 J was 59.3% (48/81) being consistent to previous study.36
Although it has been reported that obesity with sleep apnoea is
a strong predictor for the recurrence of AF after SCV,37 body
mass index was not a predictor for recurrence in this study. It
may be due to the patient group was relatively homogeneous
Asian. We did not include AF duration as a variable due to ambigu-
ousness of AF symptom in some patients with PeAF.
Conclusion
High level of TGF-b was related with failed CV. Post-CV recur-
rence was more common in patients with age .60, SEC, and
low SDF-1a levels. Under-utilization of ACE-I/ARB or spironolac-
tone was related to AF recurrence. However, LA size did not
predict AF recurrence. These predictors for AF recurrence after
CV might provide additional information in clinical decisions for
rhythm vs. rate control and RFCA vs. repeated CV, in addition
to helping with understanding of the pathophysiology.
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